StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a research report report published on Friday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.
A number of other equities research analysts also recently commented on VNDA. HC Wainwright assumed coverage on Vanda Pharmaceuticals in a report on Thursday, October 31st. They set a “buy” rating and a $18.00 target price for the company. Cantor Fitzgerald lifted their target price on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st.
Read Our Latest Analysis on Vanda Pharmaceuticals
Vanda Pharmaceuticals Trading Up 4.1 %
Hedge Funds Weigh In On Vanda Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Nantahala Capital Management LLC lifted its stake in Vanda Pharmaceuticals by 57.3% during the second quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company’s stock worth $9,003,000 after purchasing an additional 580,265 shares during the last quarter. Profit Investment Management LLC lifted its stake in Vanda Pharmaceuticals by 159.3% during the second quarter. Profit Investment Management LLC now owns 571,324 shares of the biopharmaceutical company’s stock worth $3,228,000 after purchasing an additional 351,000 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Vanda Pharmaceuticals by 17.0% during the second quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock worth $11,379,000 after purchasing an additional 292,172 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Vanda Pharmaceuticals during the first quarter worth approximately $1,158,000. Finally, Monaco Asset Management SAM purchased a new stake in Vanda Pharmaceuticals during the second quarter worth approximately $1,090,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Recommended Stories
- Five stocks we like better than Vanda Pharmaceuticals
- Where to Find Earnings Call Transcripts
- Intel: Is Now the Time to Be Brave?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is a Special Dividend?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.